← Eichor
Study identifier: NCT06968494 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction

Condition: Erectile Dysfunction Following Radical Prostatectomy  ·  Sponsor: Comphya Inc.

PhaseNA
Planned participants20
Who can joinMale, 30 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy. The main questions it aims to answer are: * Is the device safe? * Does the device works well? Are the participants satisfied with the device? Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up: * Come to the hospital for follow-up visits, * Complete questionnaires, * Activate the device every day, * Measure erection hardness. Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.

This description comes directly from the study's public registry record.

Talk to the study team

Rana Harb  ·  410-502-5500  ·  rharb1@jhmi.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Johns Hopkins HospitalBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06968494